Rigin
What do these badges mean?
Evidence tier
- AHuman-validated — Human trials showing positive results and good safety.
- BAnimal-grade — No human trials yet, but solid animal/preclinical evidence of effect and safety.
- CAnecdotal — No human or animal trials — only anecdotal/observational reports.
- DInsufficient evidence — No or insufficient evidence (encyclopedia only — never recommended by the builder).
Safety light
- 🟢 Green — Only mild, manageable side effects; reasonable safety data.
- 🟡 Yellow — Needs active management, has a meaningful contraindication/interaction, or has thin long-term data.
- 🔴 Red — Risk of a hospital-level event — treat with serious caution.
Browse-only — not on the protocol builder's curated shortlist, so the builder won't recommend it.
What is it?
Rigin is the “anti-inflammaging” peptide in the matrikine family, and a key ingredient in Matrixyl 3000 alongside Pal-GHK.
What does it do in my body?
Rigin suppresses IL-6 and other pro-inflammatory cytokine release from keratinocytes and immune cells, reducing the chronic low-grade inflammation (“inflammaging”) that accelerates skin aging.
How can it help me?
- Where the science stands: Emerging: 14 studies listed but 0 on-target human trials — most of the 14 are off-target database matches, not skin studies
The full evidence — every human, animal, and lab study, graded — is one tap away: use the See the deeper science → toggle at the top.
Is it dangerous? What are the side effects?
No adverse-effect data specific to Rigin was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status: Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Typical dosing
Educational context only — talk to a licensed medical provider before any protocol. What follows describes the doses and schedules most commonly reported in the research and by practitioners, shared so you can have an informed conversation. These compounds are sold for research use only, are not FDA-approved drugs, and this is not medical advice.
Topical-only. Commonly formulated alongside Pal-GHK in commercial blends (Matrixyl 3000). No standalone concentration figure was captured in the source profile.
What should I avoid combining — and what's synergistic?
Rigin doesn't have a dedicated stacking protocol in our notes — the interactions that matter most are in the safety section above. For how people combine it with other peptides, the deeper-science view has the full detail.
Where do people source this?
OHM does not sell or handle any compound. Research-use-only material is sold by third-party vendors; our vetting notes and disclosures are on the Where to buy page. If you'd rather have a physician in the loop, see the telehealth option. Whatever the route, the supply chain is the real risk: only consider vendors that publish batch-level third-party Certificates of Analysis.
The “anti-inflammaging” peptide and a key ingredient in Matrixyl 3000 — plausible mechanism, real role in a marketed blend, but the public study list for this exact peptide is sparse and mostly off-target database noise.
| Class | Matrikine / anti-inflammaging peptide — topical cosmetic peptide |
| Mechanism (one line) | Suppresses IL-6 and other pro-inflammatory cytokine release from keratinocytes and immune cells → reduces “inflammaging” |
| Evidence base | Emerging: 14 studies listed but 0 on-target human trials — most of the 14 are off-target database matches, not skin studies |
| Safety record | Topical-only; benign safety record (Safety: green) |
| Regulatory status | Cosmetic-grade OTC skincare ingredient, not an FDA-reviewed drug |
What it is
Rigin is the “anti-inflammaging” peptide in the matrikine family, and a key ingredient in Matrixyl 3000 alongside Pal-GHK.
How it works
Rigin suppresses IL-6 and other pro-inflammatory cytokine release from keratinocytes and immune cells, reducing the chronic low-grade inflammation (“inflammaging”) that accelerates skin aging.
What the research shows
The public profile lists 14 studies but 0 on-target human trials, graded Emerging — but most of those 14 are clearly off-target database matches (virology/MAVS-signaling papers, an antifungal-analog study), not skin studies; treat the count as profile noise rather than genuine evidence depth.
OHM’s internal 0035 categorization pass grades Rigin Tier C / green / recommend-eligible, as “Palmitoyl Tetrapeptide-7 (Sederma), small topical anti-inflammation skin trials”.
Honest status: real role in marketed blends (Matrixyl 3000), plausible anti-inflammatory mechanism, but the public study list for this exact peptide is sparse and contaminated by mismatches.
Real-world protocol
Topical-only. Commonly formulated alongside Pal-GHK in commercial blends (Matrixyl 3000). No standalone concentration figure was captured in the source profile.
Side effects & management
No adverse-effect data specific to Rigin was captured in the source profile. Family-wide read: topical delivery carries a benign safety record.
Regulatory status
Cosmetic-grade OTC topical ingredient — not an FDA-reviewed drug.
Sources
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 14 studies (mostly off-target database matches), 0 on-target human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing Sederma topical anti-inflammation trials.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Matrixyl · Syn-Coll · Tripeptide-29 · Palmitoyl Dipeptide-6 · Pal-GHK
Sources & references
- (thepeptidelist.com directory, captured 2026-06-07) — profile grade: Emerging, 14 studies (mostly off-target database matches), 0 on-target human trials.
- OHM tier/safety grading: Tier C / green / recommend-eligible, citing Sederma topical anti-inflammation trials.
- Migrated from
cosmetic-topical-peptides-cluster.md(2026-06-10 cluster build) as part of the cluster-to-standalone-article migration.
Related: Matrixyl · Syn-Coll · Tripeptide-29 · Palmitoyl Dipeptide-6 · Pal-GHK